Suppr超能文献

具有单点突变的功能失调的糖皮质激素受体消除了类固醇抗性大鼠肝癌细胞变体中CCAAT/增强子结合蛋白依赖性生长抑制反应。

Dysfunctional glucocorticoid receptor with a single point mutation ablates the CCAAT/enhancer binding protein-dependent growth suppression response in a steroid-resistant rat hepatoma cell variant.

作者信息

Ramos R A, Meilandt W J, Wang E C, Firestone G L

机构信息

Department of Molecular and Cell Biology and The Cancer Research Laboratory, University of California at Berkeley, Berkeley, California 94720, USA.

出版信息

FASEB J. 1999 Jan;13(1):169-80. doi: 10.1096/fasebj.13.1.169.

Abstract

We used glucocorticoid-resistant and -sensitive hepatoma cell variants to characterize the mechanism of hepatoma cell resistance to the growth inhibitory effects of glucocorticoids. BDS1 hepatoma cells express transcriptionally active glucocorticoid receptors and undergo a stringent G1 cell cycle arrest in response to glucocorticoids that is dependent on the induced expression of the CCAAT/enhancer binding protein alpha (C/EBPalpha) transcription factor. In contrast, EDR1 hepatoma cells, which express normal levels of glucocorticoid receptors, fail to growth arrest or express C/EBPalpha when treated with glucocorticoids. Ectopic expression of wild-type rat glucocorticoid receptors into EDR1 cells restored the growth suppression response, suggesting a defect in the EDR1 receptor. DNA sequence analysis revealed a single point mutation causing a cysteine-to-tyrosine substitution at amino acid position 457 (C457Y-GR) in the zinc finger region of the glucocorticoid receptor that mediates both receptor-DNA and receptor-protein interactions. Glucocorticoid activation of the alpha1-acid glycoprotein (AGP) promoter, a liver acute-phase response gene, requires receptor-DNA binding as well as an interaction with C/EBPalpha. In contrast to the wild-type glucocorticoid receptor, ectopic expression of C/EBPalpha in EDR1 cells, or coexpression of C/EBPalpha along with the C457Y-GR into receptor-deficient EDR3 cells was required to partially restore glucocorticoid responsiveness of the AGP promoter by the EDR1 glucocorticoid receptor. Constitutive expression of the wild-type glucocorticoid receptor, but not the C457Y-GR mutant, was sufficient to restore the glucocorticoid growth suppression response to receptor-deficient EDR3 cells. Thus, we have identified a glucocorticoid-resistant hepatoma cell variant with a single point mutation in the zinc finger region of the glucocorticoid receptor gene that ablates the glucocorticoid growth suppression response and attenuates transcriptional activation of the AGP promoter.

摘要

我们利用对糖皮质激素耐药和敏感的肝癌细胞变体来表征肝癌细胞对糖皮质激素生长抑制作用的耐药机制。BDS1肝癌细胞表达具有转录活性的糖皮质激素受体,并在糖皮质激素作用下经历严格的G1期细胞周期停滞,这依赖于CCAAT/增强子结合蛋白α(C/EBPα)转录因子的诱导表达。相比之下,表达正常水平糖皮质激素受体的EDR1肝癌细胞在接受糖皮质激素处理时,未能出现生长停滞或表达C/EBPα。将野生型大鼠糖皮质激素受体异位表达至EDR1细胞中可恢复生长抑制反应,提示EDR1受体存在缺陷。DNA序列分析显示,在糖皮质激素受体的锌指区域发生了一个单点突变,导致第457位氨基酸由半胱氨酸替换为酪氨酸(C457Y-GR),该区域介导受体与DNA以及受体与蛋白质的相互作用。α1-酸性糖蛋白(AGP)启动子是一种肝脏急性期反应基因,糖皮质激素对其激活需要受体与DNA结合以及与C/EBPα相互作用。与野生型糖皮质激素受体不同,在EDR1细胞中异位表达C/EBPα,或将C/EBPα与C457Y-GR共表达于缺乏受体的EDR3细胞中,是EDR1糖皮质激素受体部分恢复AGP启动子糖皮质激素反应性所必需的。野生型糖皮质激素受体的组成性表达,而非C457Y-GR突变体,足以恢复对缺乏受体的EDR3细胞的糖皮质激素生长抑制反应。因此,我们鉴定出一种糖皮质激素耐药的肝癌细胞变体,其糖皮质激素受体基因的锌指区域存在单点突变,该突变消除了糖皮质激素生长抑制反应并减弱了AGP启动子的转录激活。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验